High Purity Low Price Palmitoyl Tripeptide-8 Factory direct

Retatrutide is a novel multi-target receptor agonist developed by Eli Lilly and Company in the United States, primarily used for the treatment of obesity and type 2 diabetes mellitus. Its core mechanism involves simultaneous activation of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR), thereby achieving multi-faceted metabolic regulation.

Mechanism of Action

• GLP-1R Activation: Promotes insulin secretion, inhibits glucagon release, lowers blood glucose levels, delays gastric emptying, enhances satiety, and reduces food intake.
• GIPR Activation: Synergizes with GLP-1R to enhance insulin secretion, further improving glycemic control, and modulates appetite through the central nervous system.
• GCGR Activation: Stimulates energy expenditure, increases fat and glycogen breakdown, elevates basal metabolic rate, and reduces body fat storage.

Clinical Applications

• Obesity Treatment: In multiple clinical trials, Retatrutide has demonstrated significant weight loss effects. For example, in a Phase 2 trial involving obese patients, the 12 mg dose group achieved 17.5% and 24.2% weight reduction at weeks 24 and 48, respectively, outperforming existing medications.
• Type 2 Diabetes Mellitus Treatment: Retatrutide significantly lowers glycated hemoglobin (HbA1c) levels and improves glycemic control. In type 2 diabetic patients, the 12 mg dose group outperformed 1.5 mg dulaglutide in reducing HbA1c while exhibiting dose-dependent weight loss.
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Preliminary studies indicate that Retatrutide can substantially reduce hepatic fat content and improve liver function markers, offering a novel therapeutic option for non-alcoholic fatty liver disease.

Advantages

• Synergistic Multi-Mechanism Action: By activating three receptors simultaneously, Retatrutide exhibits enhanced efficacy in weight loss, glycemic control, and metabolic improvement.
• Prolonged Duration of Action: Chemical modifications confer a longer half-life, potentially enabling once-weekly dosing and improving patient adherence.
• Potential Cardiovascular and Renal Protective Effects: Although current research focuses on metabolic benefits, GLP-1R agonists have demonstrated cardiovascular and renal protective properties, which Retatrutide may inherit.